The Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) drugs in development market research report provides comprehensive information on the therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued products.
GlobalData tracks 42 drugs in development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) by 34 companies/universities/institutes. The top development phase for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) is preclinical with 21 drugs in that stage. The Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline has 40 drugs in development by companies and two by universities/ institutes. Some of the companies in the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline products market are: EpyGenix Therapeutics, Xenon Pharmaceuticals and CAMP4 Therapeutics.
The key targets in the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline products market include Sodium Channel Protein Type 1 Subunit Alpha, 5-Hydroxytryptamine Receptor, and 5-Hydroxytryptamine Receptor 2C.
The key mechanisms of action in the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline product include Sodium Channel Protein Type 1 Subunit Alpha Activator with ten drugs in Phase II. The Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline products include nine routes of administration with the top ROA being Oral and five key molecule types in the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline products market including Small Molecule, and Gene Therapy.
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) overview
Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a rare genetic disorder that causes a severe form of epilepsy. It usually starts in the first year of life with prolonged seizures triggered by fever or high temperature. Children with Dravet syndrome have various types of seizures that are difficult to treat with medications. They also have developmental delays, cognitive impairment, behavioral problems, and other neurological symptoms. Dravet syndrome is caused by mutations in the SCN1A gene, which affects the function of sodium channels in the brain. The diagnosis is based on clinical features and genetic testing. There is no cure for Dravet syndrome, but treatments aim to reduce the frequency and severity of seizures and improve the quality of life of patients and families.
For a complete picture of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
